Endogenous mechanisms of neuroprotection
神经保护的内源性机制
基本信息
- 批准号:7891343
- 负责人:
- 金额:$ 21.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-08-01 至 2010-07-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS Dementia ComplexAIDS neuropathyAntibodiesCell DeathCellsCessation of lifeChronicCognitiveDataDiseaseDominant-Negative MutationEventExposure toFunctional disorderGene ExpressionGenerationsGeneticGoalsHIV-1ImmunoblottingIn VitroIndividualInflammatoryInvestigationJUN geneKnockout MiceLaboratoriesLigandsLightMAPK14 geneMeasuresMediatingMediator of activation proteinMitogen-Activated Protein KinasesN-terminalNerve Growth Factor ReceptorsNeurologicNeurologic DeficitNeuronal DysfunctionNeuronal InjuryNeuronsNeuroprotective AgentsNeurotoxinsPathologyPathway interactionsPharmaceutical PreparationsPhosphorylationPhosphotransferasesProductionProteinsReceptor ActivationRegulationSignal PathwaySignal TransductionSpecificitySynaptic TransmissionT-LymphocyteTdT-Mediated dUTP Nick End Labeling AssayTestingViralVirus Replicationcytokinein vivoinhibitor/antagonistkinase inhibitormitogen-activated protein kinase p38mixed lineage kinase 3monocytemotor deficitneuronal survivalneuroprotectionneurotoxicneurotoxicityneurotrophic factornew therapeutic targetnovelnovel therapeuticspeptidomimeticspreventreceptorresearch studyresponsestress-activated protein kinase 1transcription factor
项目摘要
HIV-1 associated neurologic disease is believed to be the result of a chronic inflammatory state, in which
soluble neurotoxic molecules, of both viral and cellular origin, act to cause neuronal injury and dysfunction.
We hypothesize that HIV-1 neurotoxicity is opposed by a number of endogenous pathways and mediators,
which serve to protect neurons. For example, neurotrophins can augment neuronal survival and function
through the activation of specific receptors (Trk receptors) and subsequent initiation of signaling cascades.
We therefore propose to study endogenous neuroprotective pathways that may provide us with new
therapeutic strategies for neuroAIDS. This will be achieved through two specific aims. In Aim 1, experiments
will focus on signaling pathways associated with neurotrophin receptor activation, including analyses of the
neuroprotective effects of inhibitors of mixed lineage kinases (MLK)-3, p38 kinase and c-Jun NH2 terminal
kinases (JNK), as well as peptidomimetic Trk ligands. Effects on the survival and function of neurons
exposed to candidate HIV-1 neurotoxins will be evaluated, as will effects on monocyte/microglial activation.
In the second aim, we will evaluate the cell signaling events that are modulated in response to the inhibition
of MLK-3, using both pharmacological and genetic approaches. These experiments will take advantage of
available dominant negative mutants and MLK-3 knockout mice (to genetically target MLK-3), as well as
extant pharmacologic compounds and new, highly specific MLK-3 blockers that will be developed by our
commercial partner. Collectively, these investigations will identify novel neuroprotective strategies that may
enhance neuronal function and survival in neuroAIDS. Results from these studies will be correlated with
intracellular signaling events that occur in response to drug treatment, in order to identify new therapeutic
targets..
HIV-1相关的神经系统疾病被认为是慢性炎症状态的结果,其中
病毒和细胞来源的可溶性神经毒性分子可引起神经元损伤和功能障碍。
我们假设HIV-1的神经毒性受到许多内源性途径和介质的抑制,
保护神经元例如,神经营养因子可以增加神经元的存活和功能
通过激活特异性受体(Trk受体)和随后启动信号级联。
因此,我们建议研究内源性神经保护途径,可能为我们提供新的
神经艾滋病的治疗策略这将通过两个具体目标来实现。在目标1中,
将重点关注与神经营养因子受体激活相关的信号通路,包括对
混合谱系激酶(MLK)-3、p38激酶和c-Jun NH 2末端抑制剂的神经保护作用
激酶(JNK)以及拟肽Trk配体。对神经元存活和功能的影响
将评估暴露于候选HIV-1神经毒素的受试者对单核细胞/小胶质细胞活化的影响。
在第二个目标中,我们将评估响应于抑制而被调节的细胞信号传导事件。
的MLK-3,使用药理学和遗传学方法。这些实验将利用
可用的显性失活突变体和MLK-3敲除小鼠(以遗传靶向MLK-3),以及
现有的药理学化合物和新的,高度特异性的MLK-3阻滞剂,将由我们的开发
商业伙伴。总的来说,这些研究将确定新的神经保护策略,
增强neuroAIDS中的神经元功能和存活。这些研究的结果将与
为了鉴定新的治疗药物,
目标..
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HARRIS A GELBARD其他文献
HARRIS A GELBARD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HARRIS A GELBARD', 18)}}的其他基金
Immunovascular interactions in postoperative delirium superimposed on dementia (DSD).
术后谵妄叠加痴呆(DSD)时的免疫血管相互作用。
- 批准号:
10524797 - 财政年份:2022
- 资助金额:
$ 21.07万 - 项目类别:
Nanocrystal Quantum Dot Biomimetics of SARS-CoV-2 to Interrogate Neutrophil-Mediated Neuroinflammation at the Blood-Brain Barrier
SARS-CoV-2 的纳米晶量子点仿生学研究中性粒细胞介导的血脑屏障神经炎症
- 批准号:
10510611 - 财政年份:2022
- 资助金额:
$ 21.07万 - 项目类别:
Immunoprofiling postoperative delirium during aging and neurodegeneration
衰老和神经变性期间术后谵妄的免疫分析
- 批准号:
10301230 - 财政年份:2021
- 资助金额:
$ 21.07万 - 项目类别:
Immunoprofiling postoperative delirium during aging and neurodegeneration
衰老和神经变性期间术后谵妄的免疫分析
- 批准号:
10456947 - 财政年份:2021
- 资助金额:
$ 21.07万 - 项目类别:
MLKi Therapy for Cognitive Impairment in Multiple Sclerosis
MLKi 疗法治疗多发性硬化症认知障碍
- 批准号:
8904155 - 财政年份:2015
- 资助金额:
$ 21.07万 - 项目类别:
Novel Kinase and Nanoformulated Protease Inhibitors for Eradication of CNS HIV-1
用于根除 CNS HIV-1 的新型激酶和纳米制剂蛋白酶抑制剂
- 批准号:
9302543 - 财政年份:2014
- 资助金额:
$ 21.07万 - 项目类别:
Novel Kinase and Nanoformulated Protease Inhibitors for Eradication of CNS HIV-1
用于根除 CNS HIV-1 的新型激酶和纳米制剂蛋白酶抑制剂
- 批准号:
8893159 - 财政年份:2014
- 资助金额:
$ 21.07万 - 项目类别:
Novel Kinase and Nanoformulated Protease Inhibitors for Eradication of CNS HIV-1
用于根除 CNS HIV-1 的新型激酶和纳米制剂蛋白酶抑制剂
- 批准号:
8736399 - 财政年份:2014
- 资助金额:
$ 21.07万 - 项目类别:
Novel Kinase and Nanoformulated Protease Inhibitors for Eradication of CNS HIV-1
用于根除 CNS HIV-1 的新型激酶和纳米制剂蛋白酶抑制剂
- 批准号:
9107504 - 财政年份:2014
- 资助金额:
$ 21.07万 - 项目类别: